Eviti Connect study showed an increase in clinical uptake of practice-changing data

San Antonio, TX – December 11, 2019NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced new breast cancer research findings presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS).

The Symposium, held at the Henry B. Gonzalez Convention Center in San Antonio, TX from December 10-14, provides state-of-the-art information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.

NantHealth’s presentation examined how results of the phase 3 KATHERINE clinical trial, first presented at SABCS 2018 and simultaneously published in the New England Journal of Medicine (NEJM), affected treatment patterns and regimen selections among general medical oncologists in the U.S. before and after the results were publicly released. Data from NantHealth’s Eviti Connect, an evidence-based treatment intelligence and web-based oncology decision support platform, was analyzed to determine the rate of requests for treatment authorization for adjuvant Ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive early-stage breast cancer.

Study results indicated an immediate increase in T-DM1 use in the months following SABCS 2018. Based on data pulled from Eviti Connect, 95 cases would have received adjuvant T-DM1 in Q1 2019 after 0 in Q4 2018. When comparing T-DM1 and Trastuzumab use in the adjuvant breast cancer setting for HER2-positive patients, T-DM1 use since December 2018 increased and Trastuzumab use decreased as a percentage of treatment plan requests for adjuvant HER2-positive patients.

“Our research clearly shows that presenting clinical data at a leading conference like the San Antonio Breast Cancer Symposium, and having the data simultaneously published in a medical journal, influences a broad audience of oncologists,” said Sandeep “Bobby” Reddy, MD, Chief Medical Officer, NantHealth. “As results indicate an immediate increase in T-DM1 use in the months following SABCS 2018, leveraging multiple communications platforms is an important and effective way to relay practice-changing clinical data to practicing oncologists in the U.S. These forums and supporting scientific journals expose researchers, academics and medical professionals to the latest studies and ideas in the field for which they can apply to their practice.”

Title: “Real world data on treatment patterns before and after reporting of the KATHERINE trial: a phase 3 study of adjuvant Ado-trastuzumab emtansine (T-DM1) versus trastuzumab in early stage HER2+ breast cancer”
Authors: Neil Margolis Ph.D., Vlad Kozlovsky, William A. Flood MD, Sandeep K. Reddy MD
Poster Session and Number: Session 1, P1-15-08
Location: Henry B. Gonzalez Convention Center
Date and Time: Wednesday, December 11, 2019 (5:00 PM – 7:00 PM CT)

“As cancer therapies become more complex, Eviti was designed to help oncologists validate cancer treatment options and align all parties around value-based oncological care. Defining the appropriate regimens for patients is essential, and studies like this are an effective way to communicate how medical meetings and peer-reviewed journals are a valuable and timely way to get information to physicians,” said Dr. William A. Flood, CMO of Eviti.

About NantHealth:

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer®). For more information, please visit www.nanthealth.com or follow us on TwitterFacebook and LinkedIn.

Forward Looking Statement:

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

NantHealth | Technology that Simplifies Healthcare.